Evidence map›Paper›PMID 24551254›Full record

ArticlePLoS neglected tropical diseases2014

Computational studies on sirtuins from Trypanosoma cruzi: structures, conformations and interactions with phytochemicals.

Lionel Sacconnay, Melissa Angleviel, Giuseppe Marco Randazzo, Marcos Marçal Ferreira Queiroz, Emerson Ferreira Queiroz, Jean-Luc Wolfender, Pierre-Alain Carrupt, Alessandra Nurisso

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Chemical Constituents ofMolecules (Basel, Switzerland) · 2019
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry.Analytical methods : advancing methods and applications · 2016
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lionel SacconnaySchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Melissa AnglevielSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Giuseppe Marco RandazzoSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Marcos Marçal Ferreira QueirozSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Emerson Ferreira QueirozSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Jean-Luc WolfenderSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Pierre-Alain CarruptSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Alessandra NurissoSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
University of Geneva · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe silent-information regulator 2 proteins, otherwise called sirtuins, are currently considered as emerging anti-parasitic targets. Nicotinamide, a pan-sirtuin inhibitor, is known to cause kinetoplast alterations and the arrested growth of T. cruzi, the protozoan responsible for Chagas disease. These observations suggested that sirtuins from this parasite (TcSir2rp1 and TcSir2rp3) could play an important role in the regulation of the parasitic cell cycle. Thus, their inhibition could be exploited for the development of novel anti-trypanosomal compounds.

methodsHomology modeling was used to determine the three-dimensional features of the sirtuin TcSir2rp1 from T. cruzi. The apo-form of human SIRT2 and the same structure solved in complex with its co-substrate NAD(+) allowed the modeling of TcSir2rp1 in the open and closed conformational states. Molecular docking studies were then carried out. A library composed of fifty natural and diverse compounds that are known to be active against this parasite, was established based on the literature and virtually screened against TcSir2rp1 and TcSir2rp3, which was previously modeled by our group.

resultsIn this study, two conformational states of TcSir2rp1 were described for the first time. The molecular docking results of compounds capable of binding sirtuins proved to be meaningful when the closed conformation of the protein was taken into account for calculations. This specific conformation was then used for the virtual screening of antritrypanosomal phytochemicals against TcSir2rp1 and TcSir2rp3. The calculations identified a limited number of scaffolds extracted from Vismia orientalis, Cussonia zimmermannii, Amomum aculeatum and Anacardium occidentale that potentially interact with both proteins.

conclusionsThe study provided reliable models for future structure-based drug design projects concerning sirtuins from T. cruzi. Molecular docking studies highlighted not only the advantages of performing in silico interaction studies on their closed conformations but they also suggested the potential mechanism of action of four phytochemicals known for their anti-trypanosomal activity in vitro.

Indexed as

Amino Acid SequenceModels, MolecularMolecular Docking SimulationMolecular Sequence DataPhytochemicalsProtein BindingProtein ConformationProtozoan ProteinsSequence AlignmentSirtuinsTrypanosoma cruziPhytochemicalsProtozoan ProteinsSirtuins

Identifiers

PMID24551254
PMCPMC3923677
OpenAlexW2004833553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.